Individuals with advanced coronary artery disease, plaque deposits that significantly inhibit the flow of blood to the heart muscles, may need to have coronary artery bypass graft (CABG) surgery performed to alleviate the condition. While the CABG procedure is relatively safe, some patients experience serious complications after surgery, which can lead to further injury or even death.

Two recently published research studies have linked Trasylol®, a drug often used to prevent blood loss during CABG surgery, to an increased risk of kidney problems, heart attacks, and strokes. Patients who experience complications after CABG surgery should contact their medical providers to determine if Trasylol® was used for their procedure. If Trasylol® was administered, the drug may have factored into post-surgical complications.

The United States Food and Drug Administration (FDA) issued a public health advisory on February 8, 2006. The advisory states that the FDA is conducting a safety evaluation for Trasylol® to assess the drug’s risks. Doctors are warned to carefully weigh the potential benefits and risks of Trasylol® before administering the drug to patients. Patients who take Trasylol® should be monitored for toxicity to the kidneys, heart, and central nervous system. Adverse events must be promptly reported to Bayer or the FDA Medwatch program.

If you know someone who experienced kidney problems, heart attack, or stroke following CABG surgery, please register at the "Registration" link above for a free evaluation. We will contact you by phone shortly for more information.

Thank you

Technical Support - (405) 590-0181

For any technical problems please contact us immediately - Thank You

Click Here For Support